Market's view on ValiRx
Published on April 2024
- There is speculation about Martin Gouldstone potentially buying shares in ValiRx.
- Stock watchers consider AIM a good market for stock picking, with particular interest in the biotech sector, highlighting Redx as the best biotech on AIM.
- Concerns are raised about ValiRx’s board, accusing them of ineptitude and significantly damaging investments.
- Allegations are made that Suzy is drawing a significant salary for minimal work, supposedly spending time on holidays financed by the company.
- There’s a discussion about the potential merger of EUDA, noting its market cap is significantly above the minimum required for listing.
- A ‘revolution’ is mentioned concerning ValiRx, with a call for the removal of key executives likened to historical revolutions.
- Criticisms target the broader AIM market, suggesting a need for corruption and incompetence to succeed as a CEO or chairman in this sector.
- The accuracy of public statements made by ValiRx representatives is questioned, with some stock watchers demanding clarity and accountability.